Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

NCT00609869 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Lymphocytic Leukemia
Mantle Cell Lymphoma

Interventions

DRUG: Lenalidomide
DRUG: Rituximab

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]